Almac Group Announces Successful HSA Inspection of Singapore Facility
Almac Group announced that it has received a renewal of its GMP/GDP certification following the successful regulatory inspection by the Health Sciences Authority (HSA) of its facility in Singapore.
The organisation’s Asia Pacific headquarters and clinical trial supply facility was first established in Singapore in 2015 and vastly expanded Almac’s range of unique solutions offered from within the region to further optimise the clinical supply chain for both global and regional studies in their customers’ own language and time zones. This accreditation was awarded after an on-site 3 day inspection held in June 2018 confirming Almac’s compliance with the HSA standards of safety, quality and efficacy across its various operations.
Almac has continued to invest in and strengthen its in-region capabilities which are a key part of its ongoing global expansion strategy to meet market and patient needs. As part of this strategy, the facility has seen a 40% uplift in business volume, which has led to the creation of further permanent jobs at our Singapore and Japanese facilities in support of this increased demand. The successful inspection strengthens Almac’s commitment to directly support sponsors conducting regional and global studies by providing clinical manufacturing, packaging, storage, distribution, supply chain management and Interactive Response Technology (IRT).
Paul O’Connor, Global VP Quality, Almac Clinical Services, said: “Almac was the first full service clinical trial packaging and distribution organisation to ever receive GMP certification in this region when we opened our Asia-Pacific Headquarters just 3 years ago. We are delighted to receive today’s official certification which is testament to the quality and skill of our employees. We recognise the global scope, relevance and impact of our sphere of work. This successful inspection echoes our commitment to be a world leader on quality and service wherever we do business.”